{"schema_version":"secwatch.filing_event.v1","accession":"0001818331-23-000060","form_type":"8-K","ticker":"WGS","cik":"0001818331","company_name":"GeneDx Holdings Corp.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.412220+00:00","generated_at":"2026-06-12T02:35:55.319934+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GeneDx Q2 2023: Exome/genome revenue up 36% YoY; cash burn down 36%","bullets":["Continuing ops revenue $45.2M (+13% YoY); exome/genome rev. $28.7M (+36% YoY).","Exome/genome volume 11,900 tests (+56% YoY); total tests ~55,000.","Adj. gross margin 37% (pro forma), up from 34% in Q1; total adj. gross margin 42%.","Adj. net loss $41.8M, improved 37% YoY; cash burn $53M, improved 36% YoY.","FY2023 revenue guidance reaffirmed $205-220M; H2 cash use $70-85M; profitability target 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001818331-23-000060","json":"https://secwatch.observer/filing/0001818331-23-000060.json","markdown":"https://secwatch.observer/filing/0001818331-23-000060.md","text":"https://secwatch.observer/filing/0001818331-23-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818331/000181833123000060/0001818331-23-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818331/000181833123000060/smfr-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:35:55.319934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"117867f6508efcf98d473cb87160271cae8e8168","claim":"GeneDx Holdings Corp. reported the second quarter of 2023 results: revenue $48.7 million, net income $46.7 million. Guidance reaffirmed.","evidence_excerpt":"net loss for the second quarter of 2023 was $41.8 million 2 , an improvement of 37% year-over-year and 17% sequentially. · Revenue 1 : Revenue for the second quarter of 2023 was $48.7 million, compared to $36.2 million in the second quarter of 2022. · Gross Margin 1 : Gross margin for the second quarter of 2023 was 39%. Adjusted gross margin for the second quarter of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818331/000181833123000060/0001818331-23-000060-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of 2023"},{"label":"Revenue","value":"$48.7 million"},{"label":"Net income","value":"$46.7 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}